title: Bilateral analgesic effects of abobotulinumtoxinA (Dysport®) following unilateral administration in the rat.
abstract: In addition to inhibition of muscle and glandular hyperactivity, botulinum neurotoxin (BoNT) type A also interferes with pain processing. Previously, in a rat model of paclitaxel-induced polyneuropathy, abobotulinumtoxinA (aboBoNT-A) elicited analgesic effects not only in the injected paw, but also in the contralateral, non-injected paw.
  
  
  
  Here, we assessed bilateral analgesic effects of unilateral aboBoNT-A in several chronic pain models in Sprague-Dawley rats. Effects of aboBoNT-A on the paw withdrawal threshold in response to mechanical pressure was assessed in models of streptozotocin-induced diabetic polyneuropathy, chronic constriction injury (CCI)-associated mononeuropathy, and bilateral carrageenan-induced inflammatory pain.
  
  
  
  In diabetic polyneuropathy, aboBoNT-A (15, 20 U/kg) reversed hyperalgesia in the toxin-injected and non-injected paws. In unilateral CCI-exposed animals, 20 U/kg aboBoNT-A given ipsilateral to the injury reversed mechanical hyperalgesia, while 30 U/kg aboBoNT-A given contralateral to the injury had no effect. In carrageenan-induced bilateral inflammatory pain, aboBoNT-A (20, 30 U/kg) reversed hyperalgesia in both toxin-injected and non-injected paws.
  
  
  
  These results suggest that unilateral administration of aboBoNT-A results in bilateral reduction in mechanical hyperalgesia across neuropathic and inflammatory pain conditions, bilateral activation of sensory neurons being prerequisite for its expression. Future studies involving effects on other sensory modalities as well as those evaluating diffusion and migration of the toxin away from the injection site can shed light on mechanisms of this phenomenon.
  
  
  
  The results expand evidence on bilateral analgesic effects of aboBoNT-A following unilateral administration across pain modalities, as the phenomenon is seen in more than one model of polyneuropathy as well as in a model of chronic inflammatory pain when the latter is rendered bilateral. The mechanism of bilateral analgesic effects of aboBoNT-A may require activation of the peripheral sensory neurons and involve retrograde axonal transport of the toxin into the spinal cord.
authors.affiliation: Ipsen Innovation, Les Ulis, France.
authors.forename: C
authors.initials: C
authors.lastname: Favre-Guilmard
authors.affiliation: Ipsen Innovation, Les Ulis, France.
authors.forename: P-E
authors.initials: PE
authors.lastname: Chabrier
authors.affiliation: Ipsen Innovation, Les Ulis, France.
authors.forename: M
authors.initials: M
authors.lastname: Kalinichev
mesh_terms: D000700:Analgesics / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D019274:Botulinum Toxins, Type A / Q000494:pharmacology / Q000627:therapeutic use*; D059350:Chronic Pain / Q000188:drug therapy* / Q000503:physiopathology; D003929:Diabetic Neuropathies / Q000188:drug therapy* / Q000503:physiopathology; D004195:Disease Models, Animal; D006930:Hyperalgesia / Q000188:drug therapy* / Q000503:physiopathology; D007249:Inflammation / Q000188:drug therapy / Q000503:physiopathology; D008297:Male; D017288:Pain Threshold / Q000187:drug effects / Q000502:physiology; D011115:Polyneuropathies / Q000188:drug therapy* / Q000503:physiopathology; D051381:Rats; D017207:Rats, Sprague-Dawley; D013116:Spinal Cord / Q000187:drug effects / Q000503:physiopathology
chemical_list: D000700:Analgesics; D019274:Botulinum Toxins, Type A; C542869:abobotulinumtoxinA